相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Exploiting cellular pathways to develop new treatment strategies for AML
Amir T. Fathi et al.
CANCER TREATMENT REVIEWS (2010)
New agents for AML and MDS
Steven Grant
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2009)
Age-Specific Differences in Oncogenic Pathway Dysregulation and Anthracycline Sensitivity in Patients With Acute Myeloid Leukemia
Arati V. Rao et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features
Judith E. Karp et al.
CLINICAL CANCER RESEARCH (2008)
Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT)
Yukiyasu Ozawa et al.
LEUKEMIA RESEARCH (2008)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Mechanisms of Disease: cancer stem cells - targeting the evil twin
Andreas Trumpp et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
A critical role for Lyn in acute myeloid leukemia
Ceric Dos Santos et al.
BLOOD (2008)
Src family tyrosine kinases phosphorylate Flt3 on juxtamembrane tyrosines and interfere with receptor maturation in a kinase-dependent manner
Olga Mitina et al.
ANNALS OF HEMATOLOGY (2007)
STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells
Hein Schepers et al.
BLOOD (2007)
Signal transduction pathways that contribute to myeloid differentiation
M. B. Miranda et al.
LEUKEMIA (2007)
Activation mechanisms of STAT5 by oncogenic Flt3-ITD
Chunaram Choudhary et al.
BLOOD (2007)
Novel therapeutic agents in acute myeloid leukemia
Richard M. Stone
EXPERIMENTAL HEMATOLOGY (2007)
Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD
M. Okamoto et al.
LEUKEMIA (2007)
Src kinases in G-CSF receptor signaling
Matthew Sampson et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2007)
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells
S Nam et al.
CANCER RESEARCH (2005)
Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells
FM Johnson et al.
CLINICAL CANCER RESEARCH (2005)
Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations
LJ Robinson et al.
EXPERIMENTAL HEMATOLOGY (2005)
Antileukemic activity of rapamycin in acute myeloid leukemia
C Récher et al.
BLOOD (2005)
Clonogenic assay with established human tumour xenografts:: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery
HH Fiebig et al.
EUROPEAN JOURNAL OF CANCER (2004)
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
LJ Lombardo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Autocrine pathway of angiopoietins-Tie2 system in AML cells: association with phosphatidyl-inositol 3 kinase
M Wakabayashi et al.
HEMATOLOGY JOURNAL (2004)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines
F Hayakawa et al.
ONCOGENE (2000)
分享论文
